Ahhh, the good ol' days of Covid when everyone was washing their groceries and we all thought the FDA would be out of their minds to not give Leronlimab some sort of chance.

Instead of an EUA we got Nader'd & Kazempour'd. Known colloquially as "getting Pour'd" thanks to the shared four letters of their last names, it didn't just set back the company but also set back our investments. It should have been a sign that the two most important people involved with bringing Leronlimab to market had last names with the word poor in it, albeit spelled all fancy so none of us caught it.

Except Craig, probably. The king of poor understanding of the law knows poor when he sees it.

I'm anxious to the call out of the way. A betting man would predict nothing more than what we had the last time on a call, which was easily the most realistic call we've had over the past two years of squat pie*.

*There's gotta be another term that isn't "nothing burger".

For the record, I believe Cyrus when he said that 2023 would be a year of catalysts that would kick off in the first quarter of the year (paraphrasing). Add in the typical delays we never seem to be able to avoid and we should be nearing the reset of that launch. No reason it couldn't start tomorrow, though I'm taking the approach that we're still getting ducks in their rows and signing all TPS reports the way the FDA is requiring them.

Be it tomorrow or a year from now, I don't mind being poor on paper until I'm rich for real.

See you on the other side.